Last update 04 Nov 2024

COVID-19 vaccine (Shionogi)

Overview

Basic Info

Drug Type
Prophylactic vaccine, Genetically engineered subunit vaccine
Synonyms
S-268019, Covgoze, コブゴーズ
Target
SARS-CoV-2 S protein
Mechanism
SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)
Therapeutic Areas
Infectious DiseasesRespiratory Diseases
Active Indication
COVID-19
Inactive Indication-
Originator Organization
Shionogi & Co., Ltd.Shionogi & Co., Ltd.
Active Organization
Shionogi & Co., Ltd.Shionogi & Co., Ltd.Shionogi, Inc.
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (24 Jun 2024),
COVID-19
Regulation-
Login to view timeline

Related

11
Clinical Trials associated with COVID-19 vaccine (Shionogi)
JPRN-jRCT2031220493 / Not yet recruitingPhase 3IIT
A Phase 1/2/3, Randomized, Observer-Blind Study of S-268019 in Participants Aged 5 to 11 Years (Part 2)(COVID-19)
JPRN-jRCT2031220224 / Not yet recruitingPhase 2/3IIT
A Phase 2/3, Randomized, Observer-Blind, Active-Controlled Study to Compare the Immunogenicity of the fourth dose of S-268019 to the COMIRNATY intramuscular injection in Adults over 60 years of ages (COVID-19)
JPRN-jRCT2011220011 / Not yet recruitingPhase 1/2IIT
A Phase 1/2/3, Randomized, Observer-Blind Study of S-268019 in Participants Aged 5 to 11 Years (Part 1)(COVID-19)
100 Clinical Results associated with COVID-19 vaccine (Shionogi)
Login to view more data
100 Translational Medicine associated with COVID-19 vaccine (Shionogi)
Login to view more data
100 Patents (Medical) associated with COVID-19 vaccine (Shionogi)
Login to view more data
100 Deals associated with COVID-19 vaccine (Shionogi)
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
JP
Shionogi & Co., Ltd.Shionogi & Co., Ltd.
24 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05212948 (Pubmed)
ManualManual
Phase 2/3
-
204
bywrfuolnx(eeekhhqswf) = fatigue, fever, myalgia, and injection-site pain. aigxccnpnh (hoshdmflxr )
View more
Non-inferior
20 Jun 2022
BNT162b2
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free